ASCO Highlights Head and Neck Cancer
|
|
- Thomas Blair
- 5 years ago
- Views:
Transcription
1 ASCO Highlights Head and Neck Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical Oncology
2 Outline HPV Abstract 6001 HPV and tobacco Abstract 6002 HPV RTOG0129 Abstract 6004 HPV/p16 phase III EGFR Biomarkers Abstract 6005 EXTREME / EGFR FISH Abstract 6000 Mass Spectrometry ChemoXRT Abstract 6007 Darbepoetin alpha Neoadjuvant Abstract 6009 Phase III CRT vs neoadjuvant chemo-crt (PF, TPF) Thyroid Abstract 6003 Phase II Braf mutations and sorafenib
3 Abstract 6001: tobacco and HPV outcomes UMMC 0221 UMMC 9921 Retrospective review of tumor tissue from 124 pts with stage III/IV oropharynx cancer from 2 phase II chemoxrt trials. Objectives: 1) Evaluate association of HPV status and long-term outcomes 2) Evaluate effect of tobacco use on long-term outcomes in HPV positive patients Worden et al. Abstract #6001, ASCO 2009
4 Worden et al. Abstract #6001, ASCO 2009 Definitions HPV analysis: pre-treatment biopsies tested for HPV DNA by multiplex pcr/mass spect analysis (detects 15 subtypes) (Sequenome) Smoking status: determined by chart review and self-reporting Never tobacco: < 100 cigarettes per lifetime, never used any chewing tobacco/cigars/pipes Current smoker: present, including those who quit < 1 year prior to diagnosis Former smoker: Quit > 1 year prior to diagnosis
5 Patient characteristics Characteristic N=124 Male 83% Age 57 HPV (+) 82% HPV (+) never tobacco 27% HPV (+) any tobacco 56% HPV (-) never tobacco 0% HPV (-) any tobacco 18% Primary oropharynx site: BOT Tonsil other Stage III Stage IVA Stage IVB 50% 46% 4% 14% 74% 12% Tobacco status HPV (+) HPV (-) N=102 N=22 Never (n=33) 32% 0% Former (n=52) 45% 28% Current (n=39) 23% 72% Worden et al. Abstract #6001, ASCO 2009
6 Worden et al. Abstract #6001, ASCO 2009 DFS by HPV status and Treatment Efficacy by HPV status OS by HPV status and Treatment TTR by HPV status and Treatment HPV (+) status leads to improved DFS, OS, and time to disease recurrence regardless of treatment.
7 Worden et al. Abstract #6001, ASCO 2009 HPV status by tobacco usage Time to recurrence In HPV (+) pts by tobacco usage Risk of recurrence in HPV (+) patients HR P-value Current vs never Former vs never Current vs Former P=0.063 for overall effect of tobacco Smoking while HPV (+) leads to a worse time to recurrence.
8 Worden et al. Abstract #6001, ASCO 2009 Disease specific survival (DSS) Disease specific survival by tobacco usage DSS in HPV (+) pts HR P-value Current vs never Former vs never Current vs Former P=0.064 for overall effect of tobacco Smoking while HPV (+) leads to a worse DSS.
9 Worden et al. Abstract #6001, ASCO 2009 Summary Abstract 6001 In this retrospective analysis, HPV (+) tumors have better OS and DSS and less risk of recurrence than HPV (-) tumors. Patients with HPV (+) disease and current tobacco users have an increased risk of disease recurrence compared to HPV (+) never tobacco users.
10 Gillison et al. Abstract #6003, ASCO 2009 Abstract #3 Survival outcomes by HPV status in oropharynx cancer patients in RTOG 0129 Lab methodology: HPV 16 in situ hybridization (ISH) HPV 16 negative wide spectrum ISH (HPV18, 31, 33, 35, 39, 45, 52, , 68) P16 IHC Primary endpoint: Correlate HPV to OS, PFS
11 Gillison et al. Abstract #6003, ASCO 2009 Baseline Lab analysis 323 patients had oropharynx primary and HPV determination 206 (64%) were HPV-positive, 96% of which were HPV-16 P16 positive P16 negative HPV positive 192 (96%) 7 (4%) HPV negative 22 (19%) 94 (81%) Characteristic HPV + HPV - P-value Treatment 51.5% 50.4% 0.86 Age Caucasian 92.2% 75.2% <0.001 PS 68.4% 56.4% 0.03 Stage IV 87.9% 83.8% 0.3 T stage 75.2% 60.7% N stage 30.1% 38.5% 0.14 Pack years < 20 51% 22.2% <0.001
12 Overall Survival by HPV Status Variable at 2 years HPV + HPV - P-value OS rate 87.9% 65.8% <0.001 PFS rate 71.8% 50.4% <0.001 Local-regional control 13.6% 24.8% Distant mets 9.7% 12.9% 0.26 Second primary 3.9% 11.1% 0.01 Aerodigestive SPT 2.9% 7.7% 0.04 Gillison et al. Abstract #6003, ASCO 2009
13 OS by HPV and Pack Years Gillison et al. Abstract #6003, ASCO 2009 OS HR 95% CI HPV +, < 20 pack years 1 - HPV +, > 20 pack years HPV-, < 20 pack years HPV-, > 20 pack years
14 Gillison et al. Abstract #6003, ASCO 2009 Survival outcomes by HPV or p16 status Overall Survival HR 95% CI HPV-positive tumor p16 positive tumor Progression-free survival HR 95% CI HPV-positive tumor P16-positive tumor
15 Gillison et al. Abstract #6003, ASCO 2009 Summary Abstract #6003 Positive tumor HPV status predicts for improved OS and PFS in patients with oropharynx cancer, with less local-regional recurrence rates (but not distant recurrence). P16 IHC correlates with HPV tumor status and is a reasonable surrogate. Tobacco use modifies biological behavior of HPV positive tumors and leads to a worse outcome. Future trials in oropharyngeal HNSCC need to stratify patients by HPV status or p16 IHC.
16 Rischin et al. Abstract #6004, ASCO 2009 Abstract 6004 p16/hpv in phase III Retrospective review of tumor tissue from pts with stage III/IV oropharynx cancer from Phase III HeadSTART trial. HeadSTART showed no survival benefit to adding tirapazamine to cisplatin-xrt but major XRT violations were reported. Objectives: 1) Determine the prognostic significance of HPV and p16 in oropharyngeal patients from an international phase III trial
17 Rischin et al. Abstract #6004, ASCO 2009 Lab correlates HPV16/18 ISH (DAKO Genpoint Tyamide Signal Amplification System) using biotinylated probes for HPV16/18 p16 IHC (DAKO autostainer using p16 INK4a (Clone 16PO4) mouse monoclonal antibody. Nuclear and cytoplasmic staining intensity of tumor cells scored as grade 0-3 with grades 2-3 as positive.
18 Patient characteristics Characteristic HPV (+) HPV (-) P16 (+) P16 (-) n=55 N=140 N=108 N=78 Male 91% 83% 87% 81% Median Age T stage % 75% 63% 84% N stage % 73% 86% 65% PS 0 76% 65% 79% 57% Current smoker 15% 37% 15% 45% HPV and p16 positive patients have higher N-stage, are less likely to be current smokers, and had an improved PS compared to HPV/p16 negative patients (p<0.05) Rischin et al. Abstract #6004, ASCO 2009
19 Rischin et al. Abstract #6004, ASCO 2009 Overall Survival by HPV status HPV positive patients had improved OS. HPV (-) patients who received TPZ had a slight improvement in OS when compared to HPV (-) patients who received cisplatin alone.
20 HPV and p16 Failure-free survival by p16 HPV (-) but p16 (+) found in 33% cases Possible explanation: -some cases may be due to other HPV subtypes. -lack of sensitivity of HPV ISH assay (PCR analysis underway) Rischin et al. Abstract #6004, ASCO 2009
21 LRF by HPV/p16 status Time to Locoregional failure by treatment HPV or p16 (+) pts had improved LRF. Patterns of Failure HPV or p16 (-) patients who received TPZ had an improvement in LRF when compared to HPV/p16 (-) patients who received cisplatin alone; suggesting a benefit to modifying hypoxia with tirapazamine in these patients. Rischin et al. Abstract #6004, ASCO 2009
22 Overall Survival multi-variate analysis Factor Overall survival HR P-value HPV (+) vs (-) p16 (+) vs (-) Stage III vs IV PS 0 vs Hgb high vs low Rischin et al. Abstract #6004, ASCO 2009
23 Rischin et al. Abstract #6004, ASCO 2009 Summary Abstract 6004 HPV (+) oropharynx patients have an improved prognosis. p16 IHC may identify more patients than HPV ISH. Future trials need to stratify patients by HPV and p16 status The optimal treatment for HPV (+) patients is unknown but they should be treated differently than HPV (-) patients.
24 Outline HPV Abstract 6001 HPV and tobacco Abstract 6002 HPV RTOG0129 Abstract 6004 HPV/p16 phase III EGFR Biomarkers Abstract 6005 EXTREME / EGFR FISH Abstract 6000 Mass Spectrometry ChemoXRT Abstract 6007 Darbepoetin alpha Neoadjuvant Abstract 6009 Phase III CRT vs neoadjuvant chemo-crt (PF, TPF) Thyroid Abstract 6003 Phase II Braf mutations and sorafenib
25 Metastatic or recurrent HNSCC excluding NP No prior chemo unless over 8 months prior for definitive therapy PS 0-2 Phase III EXTREME Trial Stratified by prior chemo, KPS (<80 vs > 80) Primary endpoint : OS R A N D O M I Z E Platinum 5-FU Maximum 6 chemo cycles No crossover allowed Platinum 5-FU Cetuximab Q3 weeks Cisplatin 100 mg/m 2 d1 or Carboplatin AUC 5 d1 5-FU 1000 mg/m 2 d1-4 Cetuximab Weekly Cetuximab loading dose 400 mg/m 2 IV times one followed by weekly infusions at 250 mg/m 2 Vermorken et al. NEJM 359: , 2008
26 EXTREME Response Rate Vermorken et al. NEJM 359: , 2008
27 EXTREME PFS Vermorken et al. NEJM 359: , 2008
28 EXTREME Overall Survival platinum/5-fu/c225 platinum/5-fu Median OS 10.1 months 7.4 months HR p= Platinum/5-FU/C225 Platinum/5-FU Vermorken et al. NEJM 359: , 2008
29 Summary EXTREME Trial Adding cetuximab to platinum/5-fu improved overall survival over platinum/5-fu in patients with metastatic HNSCC. This is the first systemic regimen in 25 years to show a benefit over platinum-based chemotherapy in HNSCC However, quality of life needs to be considered in these patients. There was more vomiting, infusion rxn, rash with cetuximab. Also, the optimal sequencing of agents remains unclear. Identifying a biomarker to predict for treatment response is critical for optimizing treatment. Vermorken et al. NEJM 359: , 2008
30 Potential Ways of Assessing EGFR EGF Receptor (IHC) Gene Amplification (FISH) EGFR Mutation Downstream Signals / Events (eg, K-ras, B-raf, MAPKinase) Pao and Miller. JCO. 2005;23:
31 Licitra et al. Abstract #6005, ASCO 2009 Abstract #6005 Biomarker potential of EGFR FISH in the phase III EXTREME study Retrospective analysis of FISH and cellular EGFR and CEP7 signals (Dakocytomation probe mix) 312 tumors of 442 patients evaluable (71% ITT) Baseline expression of EGFR and CEP7 were equal amongst the two arms
32 Colorado FISH+ definitions > 40% of cells displayed as > 4 EGFR counts or Gene amplification is present Presence of loose or tight EGFR gene clusters with > 4 copies EGFR gene to CEP7 ratio > 2 Or 15 copies of EGFR per cell in >10% of cells Licitra et al. Abstract #6005, ASCO 2009
33 EXTREME: Chemo + cetuximab patients Licitra et al. Abstract #6005, ASCO 2009 Colorado FISH status was not predictive for benefit to Cetuximab Did not influence OS, PFS, nor RR
34 Licitra et al. Abstract #6005, ASCO 2009 EXTREME: Chemo alone patients Colorado FISH status was not prognostic Did not influence OS, PFS, nor RR
35 FISH+ by Enrichment Model Licitra et al. Abstract #6005, ASCO 2009
36 Licitra et al. Abstract #6005, ASCO 2009 None of the Enrichment Models had correlation of FISH score with PFS Example Enrichment Model B and FISH Score Each star is a patient by PFS
37 None of the Enrichment Models had correlation of FISH score with OS Licitra et al. Abstract #6005, ASCO 2009 Example Enrichment Model B and FISH Score Each star is a patient by OS
38 Summary Abstract #6005 EGFR copy number by FISH was not predictive for response or survival to cetuximab-chemotherapy treatment. Additional studies for alternative biomarkers are needed: - K-ras mutations are negative predictors in colorectal cancer (CRYSTAL trial), but in HNSCC the incidence of K-ras mutations is < 3%. Also, HNSCC do not carry EGFR mutations. Other biomarkers are needed.
39 Abstract 6000: Mass spectrometry profiling after EGFR inhibitor therapy Chung et al. Abstract #6000, ASCO 2009; Taguchi et al JNCI, 2007 MALDI is a proteomic profiling tool in serum and plasma. In NSCLC, a signature was developed that predicted for OS after EGFR TKI therapy. This profile called VeriStrat R contains 8 distinguishing mass spectrometry peaks. Theory: MS profile is reflective of EGFR dependency of the tumor regardless of histology and may predict OS in HNSCC.
40 Population Evaluated Control Cohorts N=78 HNSCC surgery N=34 HNSCC from 2 phase II trials treated with docetaxel/bortezomib or docetaxel/irinotecan EGFR Treated Cohorts N=55 Phase II gefitinib 250 mg daily N=32 Phase II erlotinib 150 mg po daily and bevacizumab 15 mg/kg every 3 wks N=21 cetuximab 400 mg/m 2 LD then 250 mg/m 2 weekly Chung et al. Abstract #6000, ASCO 2009
41 Patient Demographics Characteristic Gefitinib N=55 Erlotinib Bev N=34 C225 N=21 Control surgery N=78 Control No EGFRI N=34 Median Age Male Caucasian NR PS NR NR 7 Smoker NR 27 Best response CR 0 1 PR SD NR NR NR PD 31 9 NE 4 0 Chung et al. Abstract #6000, ASCO 2009
42 MALDI MS classification Cohorts Gefitinib N=55 Erlotinib Bev N=34 C225 N=21 Control surgery N=78 Control No EGFRI N=34 Good 56% 75% 76% 99% 65% Poor 42% 19% 24% 1% 35% Undefined 2% 3% 0% 0% 0% Failed MS 0% 3% 0% 0% 0% Chung et al. Abstract #6000, ASCO 2009
43 Overall Survival MS Profile Chung et al. Abstract #6000, ASCO 2009
44 Overall Survival MS Profile Chung et al. Abstract #6000, ASCO 2009
45 Summary Abstract #6000 Preliminary studies suggest that MALDI- MS (VeriStrat R ) has predictive ability for OS in HNSCC patients treated with EGFR inhibitors. This is consistent with the group s prior NSCLC data. Profile is predictive for both EGFR TKI and monoclonal antibody work. Chung et al. Abstract #6000, ASCO 2009
46 Outline HPV Abstract 6001 HPV and tobacco Abstract 6002 HPV RTOG0129 Abstract 6004 HPV/p16 phase III EGFR Biomarkers Abstract 6005 EXTREME / EGFR FISH Abstract 6000 Mass Spectrometry ChemoXRT Abstract 6007 Darbepoetin alpha Neoadjuvant Abstract 6009 Phase III CRT vs neoadjuvant chemo-crt (PF, TPF) Thyroid Abstract 6003 Phase II Braf mutations and sorafenib
47 Abstract 6007 Overgaard et al. Abstract #6007, ASCO 2009
48 Abstract 6007 DAHANCA 10 HNSCC, no NP Hgb < 9 mmol/l (14.5 g/dl) within 10 days of Tx PS 0-2 Radiotherapy + Darbepoetin Alpha Primary endpoint: LRC Secondary endpoint: Local control, DFS, OS, Hgb levels, early/late morbidity, compliance Stats: 80% power to detect 12% increase in LRC (n=600); interim analysis after 150 events; Due to planned interim analysis, trial stopped in Oct 2006 with 522 pts. Overgaard et al. Abstract #6007, ASCO 2009
49 Darbepoetin alpha Effect during XRT Darbepoetin alpha SAE Darbepoetin (n=260) Control (n=262) Thrombo-embolic 3% 1% Other 3% 2% Overgaard et al. Abstract #6007, ASCO 2009
50 Efficacy Overgaard et al. Abstract #6007, ASCO 2009 LRC OS Darbepoetin alpha Darbepoetin Aranesp led to a worse LRC and OS results.
51 Overgaard et al. Abstract #6007, ASCO 2009 Efficacy: DFS, cancer/non-cancer related Deaths DFS Deaths from cancer Darbepoetin alpha Darbepoetin alpha Darbepoetin led to worse DFS and more deaths from cancer. There was no difference in non-cancer related deaths. Non-cancer Related deaths
52 Overgaard et al. Abstract #6007, ASCO 2009 Subgroup analysis LRC There was no subgroup that benefited from darbepoetin
53 Overgaard et al. Abstract #6007, ASCO 2009 Summary Abstract 6007 Darbepoetin alpha should not be used concurrently with XRT in HNSCC patients it leads to a worse outcome and poorer tumor control. The reason remains unknown at this time.
54 Outline HPV Abstract 6001 HPV and tobacco Abstract 6002 HPV RTOG0129 Abstract 6004 HPV/p16 phase III EGFR Biomarkers Abstract 6005 EXTREME / EGFR FISH Abstract 6000 Mass Spectrometry ChemoXRT Abstract 6007 Darbepoetin alpha Neoadjuvant Abstract 6009 Phase III CRT vs neoadjuvant chemo-crt (PF, TPF) Thyroid Abstract 6003 Phase II Braf mutations and sorafenib
55 Induction Chemo HNSCC Trials Trial N Therapy Outcome TAX 323/EORTC NEJM 2007 TAX 324 NEJM 2007 Hitt, Madrid JCO 2005 GORTEC Calais TPF vs. PF 539 TPF vs. PF 382 Paclitaxel-PF vs. PF 220 TPF vs. PF OS benefit p=0.02 OS benefit P=0.006 OS benefit P=0.06 Larynx preservation 73% vs. 63% Paccagnella et al. ASCO 2008 abstract #6000: Induction chemo with chemoxrt versus chemoxrt alone.
56 ASCO 2009 Abstract 6009 Phase III Unresectable LAHNC No NP PS 0-1 Stage III or IV Neoadjuvant therapy x 3 Q3 wk Cisplatin 100 mg/m 2 day 1 5-FU 1000 mg/m 2 days 1-5 Cisplatin 75 mg/m 2 day 1 Docetaxel 75 mg/m 2 day 1 5-FU 750 mg/m 2 days 1-5 G-CSF primary prophylaxis ChemoXRT Cisplatin 100 mg/m 2 days 1, 22, 43 XRT to tumor Gy once daily XRT to LN 60 Gy once daily Primary endpoint: TTF Secondary endpoint: LRC, TTP, OS, safety Stats: 80% power to detect 50% increase in median TTF Hitt et al. Abstract #6009, ASCO 2009
57 Patient Demographics Characteristics CRT PF + CRT (n=128) (n=156) TPF + CRT (n=155) Median age Male 80% 93% 94% PS 0/1 26%/74% 31%/66% 29%/70% Primary tumor site Oropharynx 42% 43% 43% Hypopharynx 18% 18% 17% Larynx 20% 17% 19% Oral cavity 20% 22% 21% T4 stage 74% 80% 76% Hitt et al. Abstract #6009, ASCO 2009
58 Compliance Characteristics % received 3 cycles neoadjuvant chemo Median cycles of chemo during CRT CRT PF + CRT TPF + CRT (n=128) (n=156) (n=155) -- 76% 68% % receiving protocol XRT 80% 68% 62% Hitt et al. Abstract #6009, ASCO 2009
59 Adverse Events Grade 3/4 Toxicity CRT (n=119) PF + CRT (n=156) TPF + CRT (n=153) Neutropenia 20% 38% 34% Febrile neutropenia* 1% 3% 18% Thrombocytopenia 4% 10% 10% Asthenia 3% 9% 14% Mucositis 31% 4% 42% XRT dermatitis 8% 11% 3% *Before GCSF amendment, 22% febrile neutropenia. After GCSF amendment, Incidence of febrile neutropenia was 11%. No GI, neuro, or renal toxicity reported. Hitt et al. Abstract #6009, ASCO 2009
60 TTF Hitt et al. Abstract #6009, ASCO 2009
61 TTP Hitt et al. Abstract #6009, ASCO 2009
62 Hitt et al. Abstract #6009, ASCO 2009 LCR Rate of surgery in CRT 50% and 25% in neoadjuvant chemo-crt
63 Efficacy Efficacy CRT (n=119) PF + CRT (n=123) TPF + CRT (n=111) Total neoadj chemo (n=234) Median TTF (months) Median TTP (months) Median OS (months) Deaths during neoadj chemo Deaths during CRT HR HR HR pts 5 pts* 7 pts 2 pts 2 pts 2 pts* 4 pts *After GCSF amendment, only 1 pt treated on TPF arm died Hitt et al. Abstract #6009, ASCO 2009
64 Summary Abstract #6009 Neoadjuvant chemotherapy prior to chemoradiation is feasible and improves local-regional control. Although neoadjuvant chemo is becoming more popular, this trial does not definitive set neoadjuvant therapy as the new standard because of problems with the trial: No report on radiation quality or compliance. High rate of drop out rate from efficacy analysis (33, 44 pts missing! from neoadjuvant chemo arms). ITT analysis needs to be done. Incomplete toxicity report Efficacy report given during interim 2006 analysis reported that TPF was better than PF and CRT but now this is not the case and only 2 arms were reported on in this analysis. Hitt et al. Abstract #6009, ASCO 2009 Higher rate of deaths with chemo-crt. Emphasizes the need for patient selection and supportive therapy. A treatment benefit was seen in both neoadjuvant regimens - supports the point that it is not necessary to use TPF as neoadjuvant therapy. other options: cisplatin (75 mg/m 2 ) + docetaxel (75 mg/m 2 ) platinum + 5-FU or platinum + taxane Choice of population to treat with TPF remains to be decided.
65 Outline HPV Abstract 6001 HPV and tobacco Abstract 6002 HPV RTOG0129 Abstract 6004 HPV/p16 phase III EGFR Biomarkers Abstract 6005 EXTREME / EGFR FISH Abstract 6000 Mass Spectrometry ChemoXRT Abstract 6007 Darbepoetin alpha Neoadjuvant Abstract 6009 Phase III CRT vs neoadjuvant chemo-crt (PF, TPF) Thyroid Abstract 6003 Phase II Braf mutations and sorafenib
66 UPCC 03305: Phase II single center trial of single-agent sorafenib in patients with thyroid cancer Brose et al. Abstract #6002, ASCO 2009 Sorafenib: VEGFR, PDGFR-b, BRAF, c-kit, RET Eligibility Criteria Metastatic thyroid cancer N=55 Sorafenib Continuous 28- day dosing 400 mg po BID Primary endpoint: overall response rate Secondary endpoints: survival, safety, duration of response, PK, genetic correlates Thyroid cancer: 44% PTC have BRAF V600E gene mutations 0% FTC have BRAF V600E gene mutations
67 UPCC Patient Demographics Characteristics (n=55) % pts Male 51% Histology Papillary thyroid FTC/Hurthle cell variant Medullary thyroid Anaplastic Poorly differentiated 47% 35% 4% 7% 5% Brose et al. Abstract #6002, ASCO 2009
68 Brose et al. Abstract #6002, ASCO 2009 UPCC03305 Grade 3+ Toxicity (n=30) Adverse event % pts Atrial fibrillation 3% Hand foot syndrome 7% Rash 7% Anxiety 3% Pruritis/skin discomfort 7% HTN 10% Vomiting 3% Diarrhea 7% LFT elevation (grade 5) 3%
69 UPCC 03305: Efficacy (n=46) Brose et al. Abstract #6002, ASCO 2009 Efficacy % pts PR 36% SD 46% Median PFS 63 wks Median OS DTC only 84 wks Median OS first 30 pts only 140 wks
70 Brose et al. Abstract #6002, ASCO 2009 UPCC BRAF V600E mutation PFS (n=22) There was a trend towards improved PFS in patients with BRAF V600E mutation but it was not statistically significant.
71 Brose et al. Abstract #6002, ASCO 2009 Summary Abstract #6002 Sorafenib has clinical activity in iodine refractory metastatic differentiated thyroid cancer. Patients with BRAFV600E mutations may have a trend towards improved PFS.
72 ASCO 2009 HNSCC Conclusions - Biomarkers HPV or p16 positive oropharynx HNSCC is a unique entity with an improved prognosis and may not need as aggressive treatment as HPV/p16 negative disease. Tobacco use and hypoxia may have an influential role in HPV/p16 positive disease. Currently, there are no tumor biomarkers available for predictive use in HNSCC with regard to EGFR inhibitors. (EGFR FISH in the EXTREME trial) Mass spectrometry proteomic profiling in plasma may be promising. In thyroid cancer, sorafenib has preliminary efficacy and may be especially beneficial in BRAF V600E mutation patients.
73 ASCO 2009 HNSCC Conclusions Concurrent and Neoadjuvant therapy Darbepoetin alpha use during concurrent chemoradiation is contraindicated. Although neoadjuvant chemotherapy is commonly being used, the phase III Hitt et al. trial had some flaws and did not establish this treatment strategy as a standard of care practice. However, additional studies are underway to elucidate this issue.
74 HNSCC Tsao s Neoadjuvant Recommendations Neoadjuvant therapy is becoming accepted in standard practice. However, the optimal regimen in the specific patient population remains unknown. Induction TPF followed by weekly platinum with XRT is reasonable however, it is not always necessary to use TPF, platinum-doublets can be utilized in the appropriate patient. Low N stage - Chemoradiation may be sufficient as distant disease recurrence is modest High T stage and/or High N stage May need induction chemo but not high dose chemo-xrt. N2C disease should probably receive induction chemo. N2B if large and bulky should also be considered. Optimal induction chemo regimen remains to be seen. Would avoid induction TPF then concurrent high dose cisplatin-xrt [in SWOG 0216, this was toxic with deaths and had a poor compliance (68%)]. Cetuximab with TPF or with platinum-docetaxel is under investigation.
Head and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationSequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationSAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital
SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationHead and Neck cancer
Head and Neck cancer Medical Oncologist s Role in Multidisciplinary Teams - Focus on Adjuvant & Neo-adjuvant Therapy - Hye Ryun Kim, M.D. Yonsei Cancer Center, Medical Oncology Contents I. Introduction
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationRT +/- Surgery. Concurrent ChemoRT +/- Surgery
Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationNews Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium. Tuesday, February 13, 2018
News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium Tuesday, February 13, 2018 News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationDesign considerations for Phase II trials incorporating biomarkers
Design considerations for Phase II trials incorporating biomarkers Sumithra J. Mandrekar Professor of Biostatistics, Mayo Clinic Pre-Meeting Workshop Enhancing the Design and Conduct of Phase II Studies
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationState of the art for radiotherapy of SCCHN
State of the art for radiotherapy of SCCHN Less side effects Cured More organ & function preservation Head & neck cancer = 42 000 new cases / year in Europe Not cured Local failure Distant failure More
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationHead and NeckCancer: multi-modal therapeuticintegration
Head and NeckCancer: multi-modal therapeuticintegration P. Ponticelli, L. Lastrucci, R. De Majo, A. Rampini U.O.C. Radioterapia Ospedale S. Donato ASL 8 -AREZZO Summary Biological considerations Clinical
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationTherapy of Locally Advanced Head and Neck Cancer: State of the Art
Therapy of Locally Advanced Head and Neck Cancer: State of the Art Barbara Burtness, MD Chief, Head and Neck ncology Medical ncology Co-Leader Senior Member Fox Chase Cancer Center Philadelphia, PA Therapy
More informationHead and Neck Cancer Update Sandro V Porceddu
Head and Neck Cancer Update Sandro V Porceddu Director, Radiation Oncology Research Princess Alexandra Hospital, Brisbane Associate Professor, University of Queensland President, Trans Tasman Radiation
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationRecent Advances & Ongoing Challenges in Head & Neck Cancers
Recent Advances & Ongoing Challenges in Head & Neck Cancers Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard Medical School Boston, MA Disclosures
More informationState of the Art: Management of Squamous Cell Carcinoma of the Head and Neck. Raul Giglio
State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck Raul Giglio Disclosures Nothing to disclose SCCHN Outline 1. General considerations: MTD 2. Epidemiology 3. Locoregional disease
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationConcurrent Chemo- and Radiotherapy for Ororpharynx Cancer
Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Faye Johnson MD, PhD Associate Professor Thoracic/Head and Neck Medical Oncology August 2017 Objectives Review data that support concurrent chemo-
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationHead&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms
Head&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationMultimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) Amanda Psyrri, MD,FACP Attikon University Hospital Athens, Greece Learning objectives After reading and reviewing this material,
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationNEWER DRUGS IN HEAD AND NECK CANCER. Prof. Anup Majumdar. HOD, Radiotherapy, IPGMER Kolkata
NEWER DRUGS IN HEAD AND NECK CANCER Prof. Anup Majumdar HOD, Radiotherapy, IPGMER Kolkata 1 Included Oral cavity Nasal cavity Pharynx Larynx Lymph node in upper part of neck Excluded Brain Eye Cancer arising
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationPractice teaching course on head and neck cancer management
28-29 October 2016 - Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Nicolas Magné France
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationThe Role of Docetaxel in the Treatment of Head and Neck Cancer
GBMC Head and Neck Conference The Role of Docetaxel in the Treatment of Head and Neck Cancer Simon Best December 7, 2007 Needs assessment: Providers who participate in the care of head and neck cancer
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationOrgan-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
More informationLaryngeal and hypopharyngeal cancers
Laryngeal and hypopharyngeal cancers Induction Chemotherapy in combined modality approaches Atenas 16.09.2017 Ana Ferreira Castro, MD Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationHead, Neck, and Thyroid Cancers: Evidence-Based Approaches to Multimodal Management
Head, Neck, and Thyroid Cancers: Evidence-Based Approaches to Multimodal Management Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard Medical School
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationRecurrent or Metastatic H&N Cancer Advances and New Strategies
Recurrent or Metastatic H&N Cancer Advances and New Strategies Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium II International Symposium on Head and
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:
Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More information